Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma

Source: Leo Lens Pharma

Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhanced myopia management. The novel product will allow patients suffering from, or at a high risk of developing, myopia to wear a contact lens that can automatically and continuously deliver a drug to control myopia, such as low dose Atropine, to the patient’s eye. The MediPrint process is compatible with a variety of base contact lenses, allowing Leo Lens Pharma to pair its drug delivery technology with contact lenses designed to help slow the progression of myopia.

The use of contact lens in myopia management is not new. As the stigma of wearing glasses or spectacles leads children with myopia to look for alternatives, contact lens manufacturers have developed lenses to help slow the progression of myopia. Leo Lens Pharma aims to be the first company to pair contact lenses with the continuous delivery of drugs shown to help with myopia management.

“Myopia is a growing epidemic affecting over 2.5B people globally and we are excited to be working on a solution that could have a beneficial impact to a growing number of young patients with myopia globally,” Praful Doshi, Founder and CTO, said in a company news release. “Fortunately, this patent and development effort will benefit from the learnings out of our more immediate focus to help protect sight in the glaucoma market with a weekly continuous dosing therapy made possible by our unique MediPrint process.”

While this new patent expands Leo Lens Pharma’s IP portfolio, the company’s lead proprietary asset is a lens to treat glaucoma. This lens is manufactured with the MediPrint process, which allows for the continuous release of FDA approved bimatoprost.

Leo Lens Pharma had a successful pre-IND meeting with the FDA to confirm its regulatory strategy and will soon be submitting an IND for a phase 2a clinical trial with the glaucoma product.


Related Content